Regression of hepatic fibrosis in patients with autoimmune hepatitis (AIH) has been described in response to immunosuppressive therapy. These studies, however, besides being few in number, were conducted on adult populations. Our aim was to assess the regression of hepatic fibrosis, using morphometric assessment of fibrosis versus semi-quantitative methods, in children with AIH who achieved clinical and biochemical remission. Thirteen patients who achieved clinical and biochemical remission were included in the study, out of 62 children with AIH. Repeat biopsy was performed after 6 to 12 months of clinical and biochemical remission. Morphometric assessment of fibrosis was performed and correlated with METAVIR and Ishak semi-quantitative scores.
Results
The study group included eight male and five female patients. The median age at presentation was 4 years (range 2 to 12 years). The mean duration of treatment was 22 ± 7.3 months, and the mean interval between biopsies was 26.2 ± 6.5 months. Following therapy, there was significant reduction in aspartate aminotransferase, ALT and IgG levels as well as improvement of necroinflammation. The mean fibrosis scores were significantly decreased from 4.5 ± 1.19 and 2.9 ± 0.7 before therapy to 2.7 ± 1.16 and 2 ± 0.8 after treatment as assessed by Ishak and METAVIR scores, respectively (P = 0.001 and 0.004). The mean morphometric assessment of fibrosis before treatment was 20% ± 9.7 and following therapy it decreased to 5.6% ± 3.9 (P = 0.000).
Conclusion
Significant regression of fibrosis in paediatric AIH could occur with current therapeutic regimens. Morphometric assessment of fibrosis is more sensitive than semi-quantitative methods to identify changes in fibrosis.
Background
Autoimmune hepatitis (AIH) remains an enigmatic condition that affects children of all ages. It accounts for 2% to 5% of paediatric liver disease; however, the disease process in children appears to be more severe at presentation than commonly seen in adults, perhaps because of delay in diagnosis. Over 50% of children have cirrhosis at accession, and the disease commonly has an aggressive course [1].
AIH reflects a complex interaction between triggering factors, autoantigens, genetic predisposition and immunoregulatory networks [2]. Currently, the basic treatment of AIH is prednisone and/or azathioprine. Treatment aims at obtaining full remission not only at the clinical and biochemical levels but also at the histological level. Remission connotes disappearance of symptoms, lack of biochemical manifestations of inflammation (aspartate aminotransferase (AST) level should not be more than twice the upper normal limit, globulin levels should be normal) with the histological findings showing lack of activity or minimal activity of the process [3, 4].
Cirrhosis is an end-stage process of chronic progressive scarring inflammation produced by many causes. Once cirrhosis is established, it had been considered to be irreversible. When complications of cirrhosis such as ascites, severe encephalopathy and jaundice with variceal bleeding develop, the survival of cirrhotic patients becomes short and lethality is unavoidable. However, reports about a variety of liver disease states suggest that even established cirrhosis might be reversible with certain therapeutic regimens. Regression of fibrosis has followed phlebotomy for haemochromatosis [5], relief of chronic biliary obstruction [6] and bone marrow transplantation for thalassemia [7]. Reports suggest improvement of cirrhosis in patients with primary biliary cirrhosis treated with ursodeoxycholic acid and methotrexate [8], and also in patients with Wilson's disease treated with penicillamine [9]. Recently, there has been a documented regression of fibrosis in several patients of chronic hepatitis B and C treated with antiviral agents [10–13]. These observations in humans have been supported by murine models of hepatic injury in which biliary fibrosis has decreased after biliary decompression [14] and rabbit models in which liver fibrosis has regressed after treatment of schistosomiasis [15].
Few reports are available on the regression of hepatic fibrosis in patients with autoimmune hepatitis in response to immunosuppressive therapy [16, 17]. All these studies, however, were conducted on adult populations and only one, so far, was conducted on paediatric patients [18]. Morphometric assessment of fibrosis by image analysis is becoming more sensitive and accurate than semi-quantitative methods for the assessment of hepatic fibrosis [19, 20].
The aim of this study was to assess the possible regression of hepatic fibrosis, using the morphometric assessment of fibrosis versus semi-quantitative methods, in children with AIH treated with prednisone and/or azathioprine who achieved clinical and biochemical remission.
Methods
Study population
Thirteen patients (eight males and five females) with AIH, who achieved clinical and biochemical remission in response to treatment with prednisone and/or azathioprine, were included out of 62 patients with AIH who were seen at Mansoura University Children's Hospital, Paediatric GI and Hepatology Unit between 1999 and 2007. The remaining 49 patients were not included because they either did not have significant fibrosis (≤ 2/6, Ishak score) (0 or F1, METAVIR) at presentation, not enough time had elapsed for post-remission biopsy, had relapses, or failed to give consent.
Autoimmune hepatitis was diagnosed if the patient had chronically elevated serum aminotransferase levels, hypergammaglobulinaemia, positive autoantibodies (antinuclear antibody (ANA), anti-smooth muscle antibody (SMA), anti liver-kidney microsomal (LKM) antibody type 1), histopathological features compatible with autoimmune hepatitis on liver biopsy, and no evidence of viral infection (hepatitis B and C), metabolic (Wilson's disease, α1-antitrypsin deficiency, hemochromatosis) or drug-induced liver disease. We applied the revised scoring system for diagnosis of autoimmune hepatitis with interpretation of aggregated score; Definite AIH >15 and probable AIH 10 to 15 [21]. Included children were divided into two groups: Type 1 (ANA/SMA positive) and Type 2 (LKM-1 positive).
Treatment regimen and outcome
After diagnosis, treatment was initiated by prednisone; 2 mg/kg/day (up to 60 mg) for 2 weeks, then gradually tapered over 6 to 8 weeks, guided by the clinical and biochemical responses to a maintenance dose of 0.1 to 0.2 mg/kg/day or 5 mg daily, plus azathioprine 1 to 2 mg/kg/day (unless it is contraindicated due to cytopenia). Remission was defined as disappearance of symptoms with no flares, improvement of aminotransferase to less than twice normal (maintained for at least 1 to 2 years), restoration of serum bilirubin and γ globulin level to normal, and histological findings showing lack of activity or minimal activity. The included children underwent a second biopsy after 1 to 2 years of remission.
Histological assessment
After obtaining an informed and written consent, 26 liver biopsies from these 13 children were obtained (pre and post-treatment) by blind percutaneous biopsy (Bard gun biopsy with Tru-cut needle, gauge 16). The length of liver biopsies was 1.5 cm or more; the number of portal tracts was six or more. The cores were fixed in 10% formaldehyde-saline and processed according to routine histological techniques, until paraffin embedding.
For routine pathological diagnosis, sections were stained with haematoxylin and eosin, Masson's trichrome, and periodic acid shift before and after diastase digestion. Histological features were semi-quantitatively graded according to the Ishak modified Knodell Score [22] and METAVIR system [23]. The histological evaluation was performed systemically by one hepatopathologist (KZ) who was blinded to the clinical and serological data.
The morphometric assessment of liver fibrosis was performed by the fully automated Leica image processor with automated stage and Leica Quin software 2004. The liver biopsy slide, stained with Sirus red, was placed on the x-y motorized stage of Leica microscope. At a magnification of ×10, automated sequential digitalized images were taken and stored, then a mosaic picture was created including all the images with minimal field overlapping. This enables fibrosis assessment of the entire core at the same time. After interactive threshold, the image was converted into a binary image. Artefacts created during slide preparation were eliminated by both automatic and interactive procedures (Figure 1a to 1d). The area of the liver parenchyma was considered the reference area, then the fractional surface occupied by fibrosis was measured within the above-defined area.
Figure 1
Morphometric assessment of liver fibrosis in post-treatment biopsy using mosaic picture. a) Post-treatment mosaic picture of 93 microscopic fields (Sirus redx100). b) Delineation of the whole liver core (mosaic picture). c) Computer-assisted marking of fibrosis in binary image. d) Combined marking of fibrosis and the whole core at the same time.
Statistical analysis
The statistical analysis of data was done using SPSS program statistical package for social science version 10. The description of the data was performed in the form of mean (±) standard deviation for quantitative data and frequency and proportion for qualitative data. Non-parametric data were tested by Kolmogrov-Smirnov test and was represented as median (minimum-maximum). Pearson correlation was applied to test the association between morphometry, Ishak and METAVIR.
The analysis of the data was done to test statistically significant differences between groups. Paired sample t-test was used to compare one group at different times, and Wilcoxon test was used to compare non-parametric data at different times. P is significant if ≤ or = 0.05 at confidence interval 95%.
Results
Demographic and biochemical results
The median age at presentation was 4 years (range 2 to 12 years). Ten children were classified as Type 1 while the remaining three were Type 2. At presentation, patients had elevated alanine aminotransferase (ALT) levels (median = 243 IU/l, range 19 to 870 IU/l), AST levels (median = 170 IU/l, range 19 to 800 IU/l), and immunoglobulin G (IgG) levels (median = 27 mg/dl, range 13 to 48 mg/dl) (Table 1). The median albumin level was 3.7 g/dl (range 2.9 to 5.2 g/dl), and the median platelet count was 189,000 cells/mm3 (range 78,000 cells/mm3 to 400,000 cells/mm3). Bilirubin level was 4.5 mg/dl (range 0.5 to 17.0 mg/dl). Their prothrombin times ranged from 11 to 17 seconds. All the included patients were classified according to the revised IAHG scoring system before treatment as definite AIH, with score range from 16 to 20. There was no post-treatment reassessment, as all the included children were definite AIH before treatment (score>15).
Table 1
Laboratory investigations of the studied group before and after treatment
Before treatment
After treatment
Serial
ALT
AST
IgG
ALT
AST
IgG
1
673
600
21.8
10
45
12
2
540
560
13.3
17
47
14.5
3
585
412
48
30
36
18
4
83
85
17.3
30
22
14.4
5
50
95
28
40
45
12.6
6
870
800
23
52
53
16.3
7
156
170
32
34
49
14.8
8
314
100
27
102
91
18
9
39
19
28
26
15
14.4
10
35
40
17.7
18
22
17
11
19
26
20.6
20
24
15
12
243
230
27.8
40
48
14.4
13
502
671
30.5
19
33
16
Mean
316.0769
292.9231
25.7692
33.6923
40.7692
15.1846
Median
243
170
27
30
45
14.8
Std. Deviation
287.4275
278.2117
8.7248
23.5527
19.5796
1.8343
Minimum
19
19
13.3
10
15
12
Maximum
870
800
48
102
91
18
Duration of therapy and follow up
The follow up period varied from 2 years to 7.5 years (mean = 4.07 ± 2.9 years). The mean duration of treatment was 22 ± 7.3 months. The mean interval between diagnostic biopsies and those made to determine discontinuation of treatment was 26.2 ± 6.5 months. The mean time elapsed from clinical and biochemical remission till liver biopsy 17.8 ± 8.5 months. Following therapy, there was a significant reduction in AST, ALT and IgG levels as shown in Table 1.
Histological assessment
The mean necroinflammation score before treatment was 8.07 ± 3.5 and 2.2 ± 0.9 as assessed by Ishak and METAVIR scores respectively. Following treatment, there was a significant reduction in necroinflammation (4.6 ± 2.4 and 1.07 ± 0.6 as assessed by Ishak and METAVIR scores respectively), P = 0.004 and 0.001 (Table 2).
Table 2
Activity scores of the studied group before and after treatment
Activity before treatment
Activity after treatment
Serial
Ishak
METAVIR
Ishak
METAVIR
1
4
1
4
1
2
9
3
1
0
3
11
3
6
1
4
5
1
6
1
5
8
2
5
1
6
8
2
8
2
7
13
3
6
2
8
9
3
8
2
9
10
3
6
1
10
3
1
3
1
11
2
1
0
0
12
13
3
4
1
13
10
3
3
1
Mean
8.0769
2.2308
4.6154
1.0769
Median
9.0000
3.0000
5.0000
1.0000
Std. Deviation
3.5931
.9268
2.4337
.6405
Minimum
2.00
1.00
.00
.00
Maximum
13.00
3.00
8.00
2.00
The stage of fibrosis was assessed semi-quantitatively by both Ishak and METAVIR scores. The mean fibrosis score before treatment was 4.5 ± 1.19 and 2.9 ± 0.7 respectively. Following treatment, it decreased to 2.7 ± 1.16 and 2 ± 0.8. Such reduction was statistically significant (P = 0.001 and 0.004 for Ishak and METAVIR scores, respectively). In three children the METAVIR score remained unchanged (Table 3).
Table 3
Fibrosis scores of the studied group before and after treatment (Ishak, METAVIR, and Morphometry)
SERIAL
Before Fibrosis
After Fibrosis
Ishak
METAVIR
Morphometry%
Ishak
METAVIR
Morphometry%
1
3
2
9
3
2
3
2
5
3
18
1
1
2
3
5
3
36.3
3
2
8.1
4
5
3
27
4
3
11
5
4
3
15
1
1
2
6
3
2
13
4
3
10
7
5
3
25
4
3
1.1
8
6
4
30
4
3
12
9
5
3
32
3
2
10
10
3
2
7.9
2
1
3.4
11
3
2
5.3
1
1
1.8
12
6
4
20
3
2
5
13
6
4
21.8
3
2
3.6
Mean
4.5385
2.9231
20.0231
2.7692
2
5.6154
Median
5
3
20
3
2
3.6
Standard deviation
1.1983
0.7596
9.7827
1.1658
0.8165
3.9964
Minimum
3
2
5.3
1
1
1.1
Maximum
6
4
36.3
4
3
12
The mean morphometric assessment of fibrosis before treatment was 20% ± 9.7% and following therapy it decreased to 5.6% ± 3.9% (P = 0.000). In the three children whose METAVIR score remained unchanged, however, morphometry revealed a significant reduction in the degree of fibrosis (P < 0.001). On pre-treatment liver biopsies, Pearson correlation test revealed good correlation between Ishak and morphometry (correlation coefficient: 0.757, P < 0.01), and between METAVIR and morphometry (correlation coefficient: 0.635, P < 0.05). Furthermore, on post-treatment liver biopsies, there was a good correlation between Ishak and morphometry (correlation coefficient: 0.643, P < 0.05), and between METAVIR and morphometry (correlation coefficient: 0.636, P < 0.05) as well.
Discussion
Hepatic fibrosis is the common end point for most types of chronic liver injury. It is usually considered to be an irreversible process, especially when there is evidence of cirrhosis [24]. Recent data have challenged this belief by showing that hepatic fibrosis is a dynamic process involving an imbalance between the deposition and the degradation of fibrillar collagens and other extracellular matrix proteins [25]. Hepatic fibrosis is amenable to intervention by removing the insult and stopping the persistent inflammatory stimuli [26].
We studied thirteen patients with documented cirrhosis or extensive fibrosis at the time of diagnosis of AIH in whom clinical and biochemical remission was achieved by prednisone and/or azathioprine therapy, with significant reduction in the necroinflammatory injury in post-treatment liver biopsies. We discovered a significant regression of fibrosis in these patients after 6 to 12 months of clinical and biochemical remission.
Previous studies have demonstrated that hepatic inflammation stimulates perivascular hepatic stellate cells by cytokines, such as transforming growth factor β1 (TGF-b), These activated stellate cells are transformed into myofibroblasts; they proliferate, migrate, and degrade the normal extracellular matrix and replace it with fibril-forming collagens types I and III [27]. The matrix proteins accumulate because tissue inhibitors retard the counteractive degradative actions of matrix metalloproteinases [28]. Suppression of inflammatory activity promotes disappearance of the metalloproteinase inhibitors, degradation of the fibrotic liver matrix by unrestricted metalloproteinases, and apoptosis of the hepatic stellate cells [29, 30]. Our findings suggest that treatment with prednisone and/or azathioprine may inhibit the inciting stimulus for fibrogenesis and facilitate these anti-fibrotic actions in AIH by suppressing liver inflammation.
On the other hand, a glucocorticoid response element has been described in the human TGF-b1 gene promoter which may inhibit its expression [31]. Thus, corticosteroids may impair activation of TGF-b [32], alter its binding characteristics to matrix sites [33] and affect the ligation of TGF-b activator protein to the TGF-b element [34]. These putative anti-fibrotic actions of corticosteroids may complement their known anti-inflammatory effects to retard fibrogenesis and favour the counter-regulatory mechanisms of fibrinolysis [35, 36].
Regression of hepatic fibrosis in AIH has been reported in adult patients [16, 17, 37–39], and there is one report on regression of hepatic fibrosis in paediatric cases of AIH [18]. In all these studies the assessment of fibrosis was done only semi-quantitatively by applying Ishak score. In our study we assessed hepatic fibrosis by semi-quantitative methods applying both Ishak and METAVIR scores and by a quantitative assay, morphometry. Regression of fibrosis was evident by both methods; however, by morphometry reduction of fibrosis was more significant. Moreover, cases in which no significant reduction of fibrosis was assessed by the semi-quantitative methods, morphometry could show a significant change. Ferreira et al found no change in fibrosis score in 25% of their patients but in one patient incomplete cirrhosis developed into complete cirrhosis [18]. In 70% of their patients there was reduction in fibrosis; however, the meantime elapsed from remission to liver biopsy was longer (4.1 ± 1.5 years) than in our study (17.8 ± 8.5 months) [18]. To the best of our knowledge, this is the first time that fibrosis reversibility has been assessed by the morphometric method in paediatric patients. Our findings suggest that quantitative assessment of fibrosis may be more sensitive in assessing regression of fibrosis following treatment of AIH. It has the benefit of avoiding the inter-observer variation in the assessment of fibrosis by semi-quantitative methods. Also, morphometry can assess the actual amount of fibrosis and not only its pattern, as in semi-quantitative methods. Moreover, application of morphometry on a mosaic picture of the entire core enabled the assessment of the portal as well the parenchymal fibrosis at the same time.
Conclusion
Hepatic fibrosis and early cirrhosis are amenable to regression in patients with AIH achieving clinical and biochemical remissions in response to treatment. Early inclusion of prednisone and/or azathioprine might have great benefits on regression of fibrosis.
Morphometry is a more sensitive method to assess hepatic fibrosis regression in comparison with semi-quantitative methods (Ishak and METAVIR). Application of mosaic technology enables image analysis of the entire core without selection bias of certain areas.
Notes
Abbreviations
AIH:
Autoimmune Hepatitis
ALT:
Alanine Aminotransferase
ANA:
Anti-nuclear Antibody
AST:
Aspartate Aminotransferase
IgG:
Immunoglobulin G
LKM:
anti-liver-kidney Microsomal
SAM:
Anti-smooth Muscle Antibody
TGF-b:
Transforming Growth Factor Beta.
Declarations
Authors’ Affiliations
(1)
Department of Paediatrics, Hepatology & Gastroenterology Unit, Faculty of Medicine, Mansoura University
(2)
Department of Pathology, Faculty of Medicine, Mansoura University
(3)
Department of Internal Medicine, Hepatology & Gastroenterology Unit, Faculty of Medicine, Mansoura University
(4)
Department of Public Health, Faculty of Medicine, Mansoura University
References
Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, Mowat AP, Vergani D, Mieli-Vergani G: Autoimmune hepatitis in childhood. A 20 year survey. Hepatology. 1997, 25: 541-547. 10.1002/hep.510250308.View ArticlePubMedGoogle Scholar
Czaja AJ, Freese DK: Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002, 36: 479-497. 10.1053/jhep.2002.34944.View ArticlePubMedGoogle Scholar
Czaja AJ, Menon KVN, Carpenter HA: Sustained remission after corticosteroid therapy of type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002, 35: 890-897. 10.1053/jhep.2002.32485.View ArticlePubMedGoogle Scholar
Baranov AA, Kaganov BS, Gundobina OS, Zainudinov ZM: Autoimmune hepatitis in children. Int Pediatr. 2003, 18: 23-29.Google Scholar
Powell LW, Kerr JF: Reversal of cirrhosis in idiopathic haemochromatosis following long-term intensive venesection therapy. Australas Ann Med. 1970, 19: 54-57.PubMedGoogle Scholar
Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Lévy P: Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med. 2001, 344: 418-423. 10.1056/NEJM200102083440604.View ArticlePubMedGoogle Scholar
Muretto P, Angelucci E, Lucarelli G: Reversibility of cirrhosis in patients cured of thalessemia by bone marrow transplantation. Ann Intern Med. 2002, 136: 667-672.View ArticlePubMedGoogle Scholar
Kaplan MM, DeLellis RA, Wolfe HJ: Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med. 1997, 126: 682-688.View ArticlePubMedGoogle Scholar
Falkmer S, Samuelson G, Sjolin S: Penicillamine-induced normalization of clinical signs, and liver morphology and histochemistry in a case of Wilson's disease. Pediatrics. 1970, 45: 260-268.PubMedGoogle Scholar
Dufour JF, DeLellis R, Kaplan MM: Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci. 1998, 43: 2573-2576. 10.1023/A:1026601904609.View ArticlePubMedGoogle Scholar
Poynard T, McHutchinson J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J: Impact of interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002, 122: 1303-1313. 10.1053/gast.2002.33023.View ArticlePubMedGoogle Scholar
Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH: Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology. 1999, 117: 1229-1233. 10.1016/S0016-5085(99)70409-9.View ArticlePubMedGoogle Scholar
Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, Schoonhoven R, Brenner DA, Fried MW: Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001, 35: 749-755. 10.1016/S0168-8278(01)00218-5.View ArticlePubMedGoogle Scholar
Zimmerman H, Reichen J, Zimmerman A, Sagesser H, Thenisch B, Hoflin F: Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat. Gastroenterology. 1992, 103: 579-589.Google Scholar
Dunn MA, Cheever AW, Paglia LM, Kelly EP, Duvall RH, Andrade ZA, Goldner FH: Reversal of advanced liver fibrosis in rabbits with Schistosomiasis japonica. Am J Trop Med Hyg. 1994, 50: 499-505.PubMedGoogle Scholar
Dufour IF, Dellelis R, Kaplan MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med. 1997, 127: 981-985.View ArticlePubMedGoogle Scholar
Cotler SJ, Jakate S, Jensen DM: Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol. 2001, 32: 428-430. 10.1097/00004836-200105000-00014.View ArticlePubMedGoogle Scholar
Ferreira AR, Roquete MLV, Toppa NH, Fonseca de Castro LPF, Fagundes EDT, Penna FJ: Effect of treatment on hepatic histopathology in children and adolescents with autoimmunehepatitis. J Pediatr Gastroenterol Nutr. 2008, 46: 65-70. 10.1097/01.mpg.0000304456.84552.13.View ArticlePubMedGoogle Scholar
Goodman ZD, Becker RL, Pockros PJ, Afdhal NH: Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology. 2007, 45: 886-894. 10.1002/hep.21595.View ArticlePubMedGoogle Scholar
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M: International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999, 31: 929-938. 10.1016/S0168-8278(99)80297-9.View ArticlePubMedGoogle Scholar
Ishak K, Baptista A, Bianchi L, Callea F, Groote JD, Gudat F, Denk H, Desmet V, Korb G, MacSween RN: Histological grading and staging of chronic hepatitis. J Hepatol. 1995, 22: 696-699. 10.1016/0168-8278(95)80226-6.View ArticlePubMedGoogle Scholar
Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996, 24: 289-293. 10.1002/hep.510240201.View ArticlePubMedGoogle Scholar
Friedman SL: The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med. 1993, 328: 1828-1835. 10.1056/NEJM199306243282508.View ArticlePubMedGoogle Scholar
Olaso E, Friedman SL: Molecular regulation of fibrogenesis. J Hepatol. 1998, 29: 836-847. 10.1016/S0168-8278(98)80269-9.View ArticlePubMedGoogle Scholar
Bonis PA, Friedman SL, Kaplan MM: Is liver fibrosis reversible?. N Engl J Med. 2001, 344: 52-454. 10.1056/NEJM200102083440610.View ArticleGoogle Scholar
Friedman SL: Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 1993, 328: 1828-1836. 10.1056/NEJM199306243282508.View ArticlePubMedGoogle Scholar
Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000, 275: 2247-2250. 10.1074/jbc.275.4.2247.View ArticlePubMedGoogle Scholar
Murphy FR, Issa R, Zhou X, Rhatnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP: Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem. 2002, 277: 11069-11076. 10.1074/jbc.M111490200.View ArticlePubMedGoogle Scholar
Issa R, Williams E, Trim N, Kendall T, Arthur MJP, Reichen J, Benyon RC, Iredale JP: Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut. 2001, 48: 548-557. 10.1136/gut.48.4.548.PubMed CentralView ArticlePubMedGoogle Scholar
Parrelli JM, Meisler N, Cutroneo KR: Identification of a glucocorticoid response element in the human transforming growth factor beta 1 gene promoter. Int J Biochem Cell Biol. 1998, 30: 623-627. 10.1016/S1357-2725(98)00005-3.View ArticlePubMedGoogle Scholar
Cai J, Zheng T, Lotz M, Zhang Y, Masood R, Gill P: Glucocorticoids induce Kaposi's sarcoma cell proliferation through the regulation of transforming growth factor beta. Blood. 1997, 89: 1491-1500.PubMedGoogle Scholar
Centrella M, McCarthy TL, Canalis E: Glucocorticoid regulation of transforming growth factor beta 1 activity and binding in osteoblast enriched cultures from fetal rat bone. Mol Cell Biol. 1991, 11: 4490-4496.PubMed CentralView ArticlePubMedGoogle Scholar
Shukla A, Meisler N, Cutroneo KR: Perspective article: transforming growth factor-beta: cross road of glucocorticoid and bleomycin regulation of collagen synthesis in lung fibroblasts. Wound Repair Regen. 1999, 7: 133-140. 10.1046/j.1524-475X.1999.00133.x.View ArticlePubMedGoogle Scholar
Almawi WY, Beyhum HN, Rahme AA, Rieder MJ: Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol. 1996, 60: 563-572.PubMedGoogle Scholar
Almawi WY: Molecular mechanisms of glucocorticoid effects. Mod Asp Immunobiol. 2001, 2: 78-82.Google Scholar
Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, Hagh-Azali S, Rakhshani N, Tavangar SM, Sedaghat M, Alimohamadi SM: Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005, 50: 547-551. 10.1007/s10620-005-2472-5.View ArticlePubMedGoogle Scholar
Czaja AJ, Carpenter HA: Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004, 40: 646-652. 10.1016/j.jhep.2004.01.009.View ArticlePubMedGoogle Scholar
Schvarez R, Glaumann H, Weiland O: Survival and histological resolution of fibrosis in autoimmune chronic active hepatitis. J Hepatol. 1993, 18: 15-23. 10.1016/S0168-8278(05)80005-4.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
